Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Back

Frank Engler, PhD

Certara

Disclosure(s): Adagio Therapeutics: Advisor/Consultant

Poster(s):

226 - Higher Doses of Adintrevimab, an Extended Half-Life Monoclonal Antibody, for the Treatment and Prevention of COVID-19: Preliminary Results from a Phase 1 Single Ascending-Dose Study
Thursday, October 20, 2022
12:15 PM – 1:30 PM US ET